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Background: Central serous chorioretinopathy (CSC) has been traditionally treated with 
laser photocoagulation. We thought that transpupillary thermotherapy (TTT) utilizing a lower 
temperature than that of conventional laser photocoagulation might minimize permanent 
  retinal and choroidal damage. Studies suggest that undesirable effects on vision due to TTT 
are minimal even if it is applied to foveal and/or parafoveal lesions when TTT requires a larger 
irradiation spot. The aim of this study was to evaluate the efficacy of TTT in the management 
of atypical CSC.
Methods: We defined atypical CSC as bullous retinal detachment with diffuse or several 
leakages, severe leakage with fibrin formation under serous retinal detachment, or leakage within 
a pigment epithelium detachment. Eight consecutive patients with atypical CSC underwent visual 
acuity testing, ophthalmic examination, color photography, fluorescein angiography, and optical 
coherence tomography to evaluate the results of transpupillary thermotherapy.   Retreatment 
of atypical CSC was based on ophthalmic examination, optical coherence tomography, and 
fluorescein angiography. TTT was performed on the leaking spots shown in fluorescein 
angiography, with a power of 50–250 mW, spot size of 500–1200 µm, and exposure time of 
13–60 seconds to minimize retinal damage.
Results: In five of eight affected eyes, serous detachments completely resolved within 1 month 
after the initial TTT. One eye had persistent subretinal fluid and required a second TTT treatment. 
Two eyes showed no resolution of CSC and were treated by conventional photocoagulation. 
Initial best-corrected visual acuity (BCVA) ranged from 20/600 to 20/20 (mean, 20/40; median, 
20/30). Final BCVA ranged from 20/200 to 20/20 (mean, 20/25; median, 20/20). BCVA improved 
in all cases. Only two eyes with persistent subretinal fibrin and existing retinal pigment epithelial 
alternations in macular area showed limited improvement of BCVA despite the absence of 
subretinal exudation. The presence of retinal attachment was confirmed by optical coherence 
tomography in six eyes (75%).
Conclusions: TTT seems to be effective for the treatment of atypical CSC in the short term. 
Additional studies are necessary to evaluate the long-term effectiveness and safety.
Keywords: transpupillary thermotherapy, central serous chorioretinopathy, optical coherence 
tomography, fluorescein angiography, serous detachment
Introduction
Transpupillary thermotherapy (TTT) was introduced in 1992 as a new treatment for 
choroidal melanoma.1 TTT delivers heats to the target tissues in the form of a laser beam 
using a lower power for a prolonged period to limit damage to surrounding   tissues. This 
technique contrasts with the laser used in conventional   photocoagulation therapy in that 
the conventional laser treatment uses a high power for a short period of time, causing 
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tissue damage. Since TTT was first   performed for   choroidal 
melanoma,1 the application of TTT has been expanded 
to other malignant tumors including hemangioma,2,3 and 
  choroidal neovascularization in age-related macular degen-
eration (AMD).4,5
Central serous chorioretinopathy (CSC) has been tradi-
tionally treated with laser photocoagulation. Although recent 
articles have reported that TTT can be also utilized for the 
treatment of CSC,6,7 we thought that TTT utilizing a lower 
temperature than that of conventional laser photocoagulation 
might minimize permanent retinal and choroidal damage. 
Conventional photocoagulation results in the formation 
of scars in the retinal pigment epithelium (RPE). It can be 
applied only when retinal detachment is minimal and fluo-
rescein leaking points are few. Therefore it has limited use 
in the treatment of chronic and atypical or excessive CSC 
when retinal detachment is excessive and leaking points are 
multiple. However TTT can be applicable in those cases. 
Tranos has reported that after the TTT treatment of subfoveal 
neovascularization in AMD, vision is either maintained or 
improved in more than 70% of cases.8 This suggests that 
the undesirable effects on vision by TTT are minimal even 
if it is applied to foveal and/or parafoveal lesions when TTT 
requires a larger irradiation spot.
There is still no established therapy for atypical CSC. 
Although selected cases of acute CSC benefit from retinal 
laser photocoagulation, there is no standard treatment for 
atypical CSC.9,10 In this small pilot study, we evaluated the 
use of TTT in the management of atypical CSC.
This report is proof of the concept that TTT is at least 
effective in the short term in the treatment of serous detach-
ment associated with atypical CSC.
Subjects and methods
The study followed the Tenets of the Declaration of Helsinki. 
This study was a retrospective, uncontrolled interventional 
case series of consecutive patients with atypical CSC treated 
by TTT at Ideta Eye Hospital, Kumamoto, Japan. Patients 
who visited the hospital and were diagnosed with atypical 
CSC from April 2004 through December 2006 were included 
in this study. This study was performed with approval from 
the Ethic Board Committee of Ideta Eye hospital.
Inclusion/exclusion criteria were as follows:
Inclusion criteria:
1.  Patients selecting TTT as their first therapy.
2.  CSC patients who had documented recurrences and hoped 
for early recovery.
3.  Duration of CSC exceeding 3 months.
4.  Presence of excessive retinal detachment.
5.  Presence of multiple leaking points in fluorescein 
  angiography (FA).
6.  Presence of macular pigment epithelium detachment 
(PED) in association with CSC.
Exclusion criteria:
1.  Patients selecting conventional photocoagulation as their 
first therapy.
2.  Presence of a subfoveal leakage point in FA.
3.  Possibility of choroidal neovascularization in FA and/or 
indocyanine green angiography (IA).
The diagnosis of CSC was based on clinical appear-
ance, and the findings from FA, IA, and optical coherence 
tomography (OCT).
Treatment protocol
TTT was performed under topical anesthesia under   mydriasis. 
A slit-lamp microscope was attached to a diode laser employ-
ing near infrared diode laser radiation at a wavelength of 
810 nm. The laser parameter was determined based on the 
protocol for choroidal neovascularization. The power setting 
was set 10% lower than that of the protocol for choroidal 
neovascularization,4 because CSC has no proliferative   tissues 
and we observed scar formation in case 1, which was the 
first case treated by TTT. The spot sizes were determined 
by FA. The hyperfluorescent areas with leaking spots and 
ooze were included.
Outcome measurement
The treatment outcome was assessed by resolution of the 
serous retinal detachment on fundus examination through slit-
lamp, leakage on FA, OCT, and best-corrected visual   acuity 
(BCVA). If the retinal detachment and the angiographic 
leakage persisted more than 2 months after the treatment, 
re-treatment was performed.
Results
The study included eight eyes of eight males. Their mean age 
was 51.9 ± 12.1 years (range 39–72 years). Duration from 
onset of visual impairment to TTT ranged from 3–12 months 
(mean; 7 months).
Initial BCVA ranged from 20/600 to 20/20 (mean; 
  logMAR BCVA −0.60, median; 20/30). The mean follow-up 
period after TTT was 4.5 months (2–10 months) and BCVA 
at final follow-up ranged from 20/200 to 20/20 (mean; 
  logMAR BCVA −0.21, median; 20/20).
Anatomical success with complete resolution of 
serous retinal detachment was obtained in five eyes 
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(cases 1, 2, 3, 4, and 7) on fundus examination and OCT. 
One eye (case 5) showed only a decrease of serous retinal 
detachment with persistence of subretinal exudation lasting 
for 2 months. After the second TTT treatment the retina was 
reattached. Two eyes (cases 6 and 8) showed no resolution. 
After discussions with the patients, these two eyes were 
treated by conventional photocoagulation. Finally, anatomi-
cal success was assessed in all eyes.
BCVA improved in all patients and retinal attachment was 
achieved in six eyes (75%) (cases 2, 3, 4, 6, 7 and 8). There 
were two cases that showed no visual improvement despite 
the absence of subretinal fluid. One case (case 1) showed 
persistent subretinal fibrin while the other case (case 5) had 
RPE alternation in macula as demonstrated by OCT.
None of the cases developed severe complications except 
for extrafoveal scar formation close to the area of irradia-
tion in one eye (case 1). In two cases, the irradiation was 
discontinued before completing the planned 60-second expo-
sure time. In one case (case 1), irradiation was terminated 
at 13 seconds because of grayish retinal discoloration and 
the other case (case 2) was stopped at 45 seconds because 
of pain.
Case reports
Case 1 (Figure 1)
A 39-year-old male complained of decreased visual acuity 
for 2 months. He had a history of CSC that spontaneously 
cured. Best corrected visual acuity was 20/300 in his left eye 
at his first visit. The fundus examination revealed subretinal 
exudation and subretinal fluid (2 disk-diameters in size) in 
the macula. TTT was performed at the leakage point in FA. 
TTT was performed with a spot size of 1200 µm at a power of 
250 mW. Because retinal color changed during the irradiation, 
TTT was stopped at 13 seconds. One month after the TTT 
treatment, fundus examination and OCT revealed resolution 
of exudation and subretinal fluid. However, extrafoveal scar 
formation of the irradiated area developed. Four months after 
the treatment, his visual acuity was 20/200.
Because of this scar formation in case 1, who was the first 
case treated by TTT, we reduced the power to 90% to deliver 
a subthreshold retinal burn. We also checked the level of burn 
by performing test spots in the inferonasal quadrant.
Case 2 (Figure 2)
A 45-year-old male complained of a defect in his visual field 
for 1 month. Best corrected visual acuity was 20/20 in his left 
eye. Fundus examination showed an inferior bullous retinal 
detachment with shifting fluid and a subretinal exudation at 
the inferotemporal area, where FA showed two leak points. 
TTT was performed with 800 µm at 230 mW for 45 seconds 
for each spot. One month after the treatment, subretinal fluid 
diminished. Three months later, visual acuity was 20/20.
Case 3 (Figure 3)
A 45-year-old male complained of visual loss for 1 month. 
Best corrected visual acuity was 20/600. There were three 
retinal pigment epithelium detachments (PED) and serous 
retinal detachment superiorly. FA showed the leakage point 
in PED superior to the optic disk. TTT was performed at 
the leakage point in PED with a spot size of 500 µm and a 
power of 50 mW for 60 seconds. The subretinal fluid disap-
peared within 2 weeks. Three months later, visual acuity 
was 20/100.
Discussion
The current concept of underlying pathology in CSC is 
abnormal choroidal hyperpermeability. Typically, one or 
more discrete isolated leaks are detected at the level of the 
retinal pigment epithelium (RPE) in FA. Figure 1A also 
demonstrates multifocal choroidal hyperpermeability fol-
lowing focal hypofluorescent lesions. This suggests that the 
A1 A2
B1 B2
C1 C2
Figure  1  Case  1:  Color  fundus  photography  shows  serous  detachment  and 
yellowish exudates under the retina in the macular area (A1). OCT shows subretinal 
fibrin, subretinal fluid, and pigment epithelial detachment before treatment (B1). 
Fluorescein leaking point is temporal to the macular lesion (C1). Post-treatment 
color  photograph  shows  no  serous  detachment  (A2).  OCT  shows  no  retinal 
detachment but minimal RPE detachment and extrafoveal scar formation at the 
irradiation area (B2). Fluorescein leakage had subsided (C2).
Abbreviations:  OCT,  optical  coherence  tomography;  RPE,  retinal  pigment 
epithelium.
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initial choroidal vascular compromise leads to dysfunction 
in the overlying RPE, which eventually causes serous retinal 
detachment and exudation.11,12
Typical cases of CSC have been reported to spontane-
ously resolve in 1–3 months,13 without requiring particular 
treatment. In about 10% of cases, however, resolution of reti-
nal detachment does not occur, leading to RPE damage.12,14,15 
Since the RPE damage causes retinal and/or pigment epi-
thelial detachments that determine the prognosis of visual 
recovery,16 CSC without spontaneous resolution needs a 
proper and timely treatment. Typical CSC with a discrete 
leak point can be treated with photocoagulation, but chronic 
and atypical variants of CSC are sometimes difficult to treat. 
Moreover, to date, no standard treatment for atypical or 
excessive CSC has been established. Conventional photoco-
agulation cannot be used in subfoveal lesions. The grid laser 
photocoagulation for atypical CSC, reported by Yannuzzi 
et al,10 produced anatomical resolution in retinal detachments. 
However, it failed to improve the visual outcome.
Acute visual loss after photodynamic therapy was 
reported. Transient choroidal ischemia after photodynamic 
therapy (PDT) with verteporfin in AMD has been observed 
previously in human and animal studies. Subthreshold TTT, 
which could avoid damaging the overlying neural retina 
may not cause acute vision loss and could be applied to any 
patient.17 Furthermore, PDT is not practical in most countries 
because of economic reasons. TTT is a less expensive tool and 
has been recently reported to accelerate the resolution of CSC 
and improve the visual outcome.6,7 The present study also 
demonstrates that TTT may be a safer alternative treatment 
than PDT for atypical variants of CSC. The mechanism by 
which treatment with raised temperature leads to the repair 
of RPE damage has not been well understood. This report 
provides no information on this issue, either. However, it is 
certain that damage to photoreceptors has to be minimal to 
obtain a reasonable visual outcome. The laser beam with   
an 810 nm wavelength that is used in TTT is predominantly 
absorbed by pigmented cells and the choroid, whereas 
absorption by xanthophylls in photoreceptors is relatively 
low.18 This may explain the difference in the susceptibility to 
temperature increase between the sensory retina and   choroid. 
TTT upregulates the expression of heat shock proteins, 
which protect the cells from various insults,19,20 including 
the choroidal layers.21 This also implies that although TTT 
may result in cellular damage in retinal layers,22 the adverse 
effects can be minimized by carefully selecting the laser 
treatment variables of TTT for CSC.23 Standard photoco-
agulation that uses hyperthermia at .45°C exerts a direct 
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Figure 2 Case 2: Color fundus photography shows yellowish lesion inferotemporal 
to  the  fovea  (black  arrow)  (A1).  OCT  shows  subretinal  fluid  with  fibrin  and 
possible  RPE  elevation  (B1).  Fluorescein  angiography  shows  two  leakage 
points (white arrow) (C1). Post-treatment color photograph shows no yellowish 
exudate  (black  arrow)  (A2).  OCT  shows  decreased  subretinal  fluid  and  RPE 
detachment (B2). Fluorescein leakage had subsided (C2).
Abbreviations:  OCT,  optical  coherence  tomography;  RPE,  retinal  pigment 
epithelium.
A1 A2
B1 B2
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Figure 3 Case 3: Color photography shows bullous retinal detachment located 
superior to the disk and fovea (A1). Note the large fluorescein staining area superior 
to the disk (B1), two leaking spots at the inferotemporal quadrant and fluorescein 
accumulation in the subretinal space superior to the macula (B3). Post-treatment 
color fundus photography shows subsidence of bullous retinal detachment (A2). 
Decrease of fluorescein leakage (B2). Fluorescein staining remained with no obvious 
enlarging in FA (B4).
Abbreviation: FA, fluorescein angiography.
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and irreversible cytotoxic effect resulting in cell necrosis, 
which causes scar formation and often neovascularization. 
Less invasive treatment by TTT may have an advantage over 
standard photocoagulation in atypical CSC when leaking 
points are multiple.
Our findings demonstrated the efficacy of TTT in atypical 
CSC, and also suggests that it can be applied to typical CSC 
when serous retinal detachment superimposes the leaking 
point. This pilot study, however, demonstrates only short-term 
safety and efficacy. Because even clinically subthreshold TTT 
could damage the neural retina,24 the establishment of the 
appropriate parameters of TTT will be necessary. Long-term 
randomized controlled studies on a large scale are needed to 
determine the appropriate power and duration of TTT and 
ensure its safety.
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